Overview

The Efficacy of Transarterial Chemoinfusion (TAI) Combine Lenvatinib in Advanced Hepatocellular Carcinoma (HCC)

Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
evaluation of the efficacy of transarterial chemoinfusion (TAI) combine lenvatinib in advanced hepatocelllar carcinoma
Phase:
Phase 3
Details
Lead Sponsor:
Sun Yat-sen University
Treatments:
Lenvatinib